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ABSTRACT  
In the recent years, scientific and technological advancements have been made in the research and development of novel drug delivery systems by overcoming 
physiological troubles such as short gastric residence times and unpredictable gastric emptying times. Oral route is the most preferable route of administration 
but it has certain limitation for those drugs which absorb from upper part of GI tract or having narrow absorption window. The bioavailability of these drugs 
can be improved by increasing the residence of the dosage form in the stomach. The gastric residence time of the dosage form can be improved by formulating 
them as floating drug delivery system. The current & recent developments of Stomach Specific cardiovascular drugs formulated as FDDS are discussed in this 
review. 
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INTRODUCTION 
Oral delivery of drugs is by far the most preferable route of 
drug  delivery  due  to  ease  of  administration,  patient 
compliance  and  flexibility  in  formulation  etc.  Drug 
absorption in gastrointestinal (GI) tract may be very short and 
highly variable in certain Circumstances.  
Drugs  having  short  circulating  half-life  and  restricted 
absorption  via  a  defined  segment  of  intestine  limits  the 
therapeutic potential of many drugs. Such a pharmacokinetic 
limitation  leads  in  many  cases  to  frequent  dosing  of  the 
medication to achieve therapeutic effect. This results in pill 
burden  and  consequently,  patient  complains.  The 
phenomenon of absorption via a limited part of the GIT has 
been termed the narrow absorption window; once this dosage 
form passes the absorption window the drug will be neither 
bioavailable  nor  effective.  In  extreme  cases  drugs  that  are 
insufficiently  absorbed  due  to  narrow  absorption  window 
cannot  be  delivered  entirely  and  are  either  given  by  the 
parenteral  route  or  the  development  of  such  medication, 
which deliver the drug in control manner, which is safe
1,2. 
Control release implies the predictability and reproducibility 
to control the drug release, drug concentration in target tissue 
and  optimization  of  the  therapeutic  effect  of  a  drug  by 
controlling  its  release  in  the  body  with  lower  and  less 
frequent dose.
3 
Oral controlled drug dosage forms for past three decades due 
to their considerable therapeutic advantages. However, this 
approach has been suitable for a variety of important drugs, 
characterized by narrow absorption window in upper part of 
the  gastrointestinal  tract,  i.e.  stomach  and  upper  part  of 
intestine (duodenum). 
An  ideal  dosage  form  is  one,  which  attains  the  desired 
therapeutic  concentration  of  drug  in  plasma  and  maintains 
constant  for  entire  duration  of  treatment.  This  is  possible 
through administration of a conventional dosage form in a 
particular dose and at particular frequency. In most cases, the 
dosing intervals much shorter than the half life of the drug 
resulting in a number of limitations associated with such a 
conventional dosage form are as follows: 
Poor  patient  compliance;  increased  chances  of  missing  the 
dose  of  a  drug  with  short  half-life  for  which  frequent 
administration is necessary. 
A typical peak plasma concentration time profile is obtained 
which makes attainment of steady state condition difficult. 
The unavoidable fluctuation in the drug concentration may 
lead to under medication or over medication as the steady 
state  concentration  values  fall  or  rise  beyond  in  the 
therapeutic range. 
The  fluctuating  drug  levels  may  lead  to  precipitation  of 
adverse  effects  especially  of  a  drug  with  small  therapeutic 
index whenever overmedication occurs. 
The above problems can be over come by the development of 
effective and safer use of existing drugs through concepts and 
technique of controlled and targeted drug delivery system
4,5 
The controlled drug delivery system is one, which delivers 
the drug at a predetermined rate, locally or systemically for a 
predetermined period of time. 
The advantages of controlled drug delivery system over 
the conventional dosage form are as follows: 
1. Improved patient convenience and compliance due to less 
frequent drug administration. 
2. Reduction in fluctuation in steady state levels and therefore 
better control of disease condition and reduced intensity of 
local or systemic side effects. 
3. Increased safety margin of high potency drugs due to better 
control of plasma levels. 
4. Maximum utilization of drug enabling reduction in total 
amount of dose administered. 
5. Reduction in health care costs through improved therapy, 
shorter treatment period, less frequency of dosing. 
Under certain circumstances prolonging the gastric retention 
of  a  delivery  system  is  desirable  for  achieving  greater 
therapeutic  benefit  of  the  drug  substances.  For  example, 
drugs  that  are  absorbed  in  the  proximal  part  of  the 
gastrointestinal tract
6, and the drugs that are less soluble or 
are degraded by the alkaline pH may benefit from the prolong 
gastric retention
7,8. In addition, for local and sustained drug 
delivery to the stomach and the proximal small intestine to 
treat  certain  conditions,  prolonging  gastric  retention  of  the 
therapeutic moiety may offer numerous advantages including 
improved  bioavailability,  therapeutic  efficacy  and  possible 
reduction of the dose size.
9,10 
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Approaches To Gastric Retention  
Various  approaches  have  been  paused  to  increase  the 
duration  of  oral  dosage  form  in  the  stomach,  including 
floating systems, swelling and expanding system, modified 
shape system, high density systems and other delayed gastric 
emptying  devices.  (Magnetic  systems,  Super  porous  –
biodegradable hydrogel systems).  
1. Hydrodynamically balanced systems (HBS) –incorporated 
buoyant materials enable the device to float.
11,12,13 
2.  Raft  systems  incorporate  alginate  gels  –  these  have  a 
carbonate  component  and, upon reaction  with  gastric  acid, 
bubbles form in the gel, enabling floating.
11,12 
3. Swelling type of dosage form are such that after swelling, 
this product swell to extent that prevent their exit from the 
stomach through the pylorus. As, a result, the dosage form 
retained in the stomach for a longer period of time. These 
systems may  be referred to as a “Plug type system”, since 
they  exhibit  tendency  to  remain  logged  in  the  pyloric 
sphincters.
14 
4. Bioadhesive or mucoadhesive systems are used to localize 
a delivery device within the lumen and cavity of the body to 
enhance  the  drug  absorption  process  in  a  site-specific 
manner.  The  approaches  involves  the  use  of  bioadhesive 
polymers that can be adhere to the epithelial surface of the 
GIT.  The  proposed  mechanisms  of  bioadhesive  is  the 
formation of hydrogen and electrostatic bonding at the mucus 
polymer boundary.
15 
5. Modified shape systems are non-disintegrating geometric 
shapes  molded  from  silastic  elastomer  or  exuded  from 
polyethylene blends and extended the GTT depending on the 
size,  shape  and  flexural  modulus  of  the  drug  delivery 
device.
16 
6. High density formulations include coated pallets, and have 
density  greater  than  that  of  the  stomach  content  (1.004 
gm/cm
3). This is accomplishing by coating the drug with a 
heavy inert material such as barium sulphate, ZnO, titanium 
dioxide. This formulation of high-density pellet is based on 
assumption  that  heavy  pellets  might  remain  longer  in  the 
stomach,  since  they  are  position  in  the  lower  part  of  the 
antrum.
17 
7. Another delayed gastric emptying approaches of interest 
include  sham  feeding  of  digestible  polymers  or  fatty  acid 
salts that charges the motility pattern, of the stomach to a fed 
stage  thereby  decreasing  the  gastric  emptying  rate  and 
permitting considerable prolongation of the drug release. 
Hydrodynamically  Balanced  System  or  Floating  drug 
Delivery System
18,19 
Floating systems or Hydrodynamically controlled systems are 
low-density  systems  that have  sufficient  buoyancy  to  float 
over the gastric contents and remain buoyant in the stomach 
without affecting the gastric emptying rate for a prolonged 
period of time. While the system is floating on the gastric 
contents, the drug is released slowly at the desired rate from 
the  system.  After  release  of  drug,  the  residual  system  is 
emptied from the stomach. This result sin an increased GRT 
and  a  better  control  of  the  fluctuations  in  plasma  drug 
concentration.  However,  besides  a  minimal  gastric  content 
needed  to  allow  the  proper  achievement  of  the  buoyancy 
retention principle, a minimal level of floating force  is also 
required  to  keep  the  dosage  form  reliably  buoyant  on  the 
surface  of  the  meal.  Many  buoyant  systems  have  been 
developed  based  on  granules,  powders,  capsules,  tablets, 
laminated films and hollow microspheres.  
 
 
Advantages of floating drug delivery system 
Prolonged gastric retention improves bioavailability, reduces 
drug  waste  and improves  solubility  for  drugs  that are  less 
soluble in a high pH environment. It has applications also for 
local  drug  delivery  to  the  stomach  and  proximal  small 
intestines. Gastro retention helps to provide better availability 
of  new  products  with  new  therapeutic  possibilities  and 
substantial benefits for patients. 
1.  The  gastroretensive  systems  are  advantageous  for  drugs 
absorbed through the stomach. E.g. Ferrous salts, antacids. 
2.  Acidic  substances  like  aspirin  cause  irritation  on  the 
stomach  wall  when  come  in  contact  with  it.  Hence  HBS 
formulation may be useful for the administration of aspirin 
and other similar drugs. 
3. Administration of prolongs release floating dosage forms, 
tablet or capsules, will result in dissolution of the drug in the 
gastric  fluid.  They  dissolve  in  the  gastric  fluid  would  be 
available for absorption in the small intestine after emptying 
of the stomach contents. It is therefore expected that a drug 
will  be  fully  absorbed  from  floating  dosage  forms  if  it 
remains in the solution form even at the alkaline pH of the 
intestine. 
4.  The  gastroretensive  systems  are  advantageous  for  drugs 
meant for local action in the stomach. e.g. antacids. 
5. When there is a vigorous intestinal movement and a short 
transit time as might occur in certain type of diarrhea, poor 
absorption is expected. Under such circumstances it may be 
advantageous  to  keep  the  drug  in  floating  condition  in 
stomach to get a relatively better response. 
Disadvantages of floating drug delivery system
18,19 
Floating  system  is  not  feasible  for  those  drugs  that  have 
solubility or stability problem in G.I. tract. 
1. These systems require a high level of fluid in the stomach 
for drug delivery to float and work efficiently-coat, water. 
2.  The  drugs  that  are  significantly  absorbed  through  out 
gastrointestinal  tract,  which  undergo  significant  first  pass 
metabolism, are only desirable candidate. 
3. Some drugs present in the floating system causes irritation 
to gastric mucosa. 
CARDIOVASCULAR DISEASE 
Globally, cardiovascular diseases are the number one cause 
of death and they are   projected to remain so. An estimated 
17 million people died from cardiovascular disease in 2005, 
representing 30% of all global deaths. 
Of these deaths, 7.2 million were due to heart attacks and 5.7 
million due to stroke. About 80% of these deaths occurred in 
low-  and  middle-income  countries.  If  current  trends  are 
allowed  to  continue,  by  2030  an  estimated  23.6  million 
people  will  die  from  cardiovascular  disease  (mainly  from 
heart attacks and strokes).
20 
Cardiovascular diseases include:  
Coronary heart disease (heart attacks),  
Cerebrovascular disease,  
Raised blood pressure (hypertension),  
Peripheral artery disease,  
Rheumatic heart disease,  
Congenital heart disease, and 
Heart failure.  
Cardiovascular drugs belong to different category have been 
found to be good candidate of gastro retentive drug delivery 
system.  The  current  review  deals  with  the  floating  drug 
delivery  system  that  have  been  develop  to  improve  the 
therapeutic efficacy of such drugs. 
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Table 1-Various floating dosage form used in treatment of 
cardiovascular disease 
S. 
No. 
Dosage form  Drug  Reference 
1.  Floating 
granules 
Diltiazem HCl  Shimpi et al.; 2004 
2.  Floating 
Microspheres 
Nifedipine  Soppimath et al.; 
2001 
3.  Floating 
Microspheres 
Verapamil HCl  Tanwar Y.S. et al.; 
2007 
4.  Floating 
Microspheres 
Atenolol  Patel A.R. et al. ; 
2011 
5.  Floating 
Microspheres 
Captopril  Dhole R.A. et al.; 
2011 
6.  Floating 
Microspheres 
Diltiazem HCl  Streubel et al.; 2003 
7.  Floating 
Microspheres 
Nifedipine  Ling Zhao et al.; 
2010 
8.  Floating 
Microspheres 
Metoprolol 
Tartarate 
Baskar G.Y. et al.; 
2010 
9.  Floating 
Microspheres 
Losartan  Chen R.N., et al. ; 
2010 
10.  Floating  tablet  Nifedipine  Sreekanth et al.; 
2011 
11.  Floating tablet  Atenolol  Gangadharappa 
H.V. et al.; 2010 
12.  Floating tablet  Diltiazem HCl  Patel N.A. et. al. ; 
2011 
13.  Floating tablet  Nimodipine  Wu et al.; 1997 
14.  Floating tablet  Nicardipine 
HCl 
Moursy et al.; 2003 
15.  Floating tablet  Sotalol HCl  Zia et al.; 1999 
16.  Floating tablet  Captopril  Singh S et al, 2011 
17.  Floating beads  Nicardipine 
HCl 
Takka S. et al.; 
1998 
 
An overview of floating drug delivery system research of 
cardiovascular drugs 
Floating granules 
These granules floated for long time in gastric fluid and rate 
of drug release from the granules was depends upon polymer 
concentration.  
Shimpi et al., 2004, prepared floating granules of Diltiazem 
Hydrochloride  using  Gelucire  43/01  by  melt  granulation 
technique. The granules were retained in stomach for 6 hours 
and approximately 65 to 85 % drug was released over 6 hours 
with initial fast release from the surface.
21 
Floating Microspheres 
Soppimath  et  al.,  2001,  prepared  hollow  microspheres  of 
cellulose  acetate  loaded  with  four  cardiovascular  drugs 
(Nifedipine,  Nicardipine  HCl,  Varapamil  HCl  and 
Dypiridamole) were prepared by a novel solvent diffusion-
evaporation  method.  The  O/W  emulsion  prepared  in  an 
aqueous solution of 0.05% poly (vinyl alcohol) medium with 
ethyl acetate, a water-soluble and less toxic solvent, was used 
as a dispersing solvent. The yield of the microspheres was up 
to  80%.  The  microspheres  had  smooth  surfaces,  with  free 
floating  and  good  packing  properties.  Scanning  Electron 
Microscopy  (SEM)  confirmed  their hollow  structures,  with 
sizes in the range of 350-489 mm. The microspheres were 
tended to float over the gastric media of more than 12 hrs.
22 
Yuveraj Singh Tanwar et al., 2007, prepared and evaluation 
of  floating  microspheres  of  verapamil  hydrochloride  for 
improving the drug bioavailability by prolongation of gastric 
residence time. Cellulose acetate, acrycoat S100 and eudragit 
S100  microspheres  loaded  with  verapamil  hydrochloride 
were prepared by solvent diffusion evaporation method.
23 
Arpan  R  Patel  et  al.,  2011,    prepared  and  evaluation  of 
floating  microspheres  of  atenolol  for  improving  the  drug 
bioavailability by prolongation of gastric residence time. A 
controlled-release system designed to increase residence time 
in the stomach without contact with the mucosa was achieved 
through  the  preparation  of  floating  microspheres  by  the 
emulsion solvent diffusion technique, using calcium silicate 
(CS) as porous carrier; (ii) Atenolol, an oral antihypertensive 
agent; and (iii) Eudragit® S as polymer. . The microspheres 
were found to be regular in shape and highly porous. The 
prepared microspheres exhibited prolonged drug release and 
remained buoyant for >10 h. The mean particle size increased 
and  the  drug  release  rate  decreased  at  higher  polymer 
concentrations.
24 
A.R.Dhole et al., 2011 prepared and evaluation of floating 
microcarriers of Captopril as model drug for prolongation of 
gastric residence time. The microcarriers were prepared by 
Ionotropic  gelation  technique  using  polymers  Sodium 
alginate  along  with  Hydroxyl  propylmethylcellulose  and 
Ethyl  cellulose.  The  prepared  microcarriers  exhibited 
prolonged drug release and remained buoyant for > 12 h. The 
mean  particle  size  increased  and  the  drug  release  rate 
decreased as the concentration of polymer increases.
25 
Streubel  et  al.,  2003,  developed  low  density  foam 
(Polypropylene)  based  microparticles  using  diltiazem 
hydrochloride,  theophylline  or  verapamil  hydrochloride  as 
model drug and eudragit RS or polymethyl methacrylate as 
polymer. The floating micro particle showed a good in- vitro 
floating behavior and a broad variety of drug release pattern 
depending upon the drug loading and polymer used.
26 
Kulkarni  et  al.,  2008,  design  bilayer  floating  tablets  of 
diltiazem  HCI  and  lovastatin to  give  immediate release  of 
lovastatin and controlled release of diltiazem HCl and studied 
the influence of presence of one drug on the release pattern of 
other  drug.  The  bilayer  tablets  consist  of  sodium  starch 
glycolate as superdisintegrant for lovastatin in the immediate 
release  layer  and  hydroxypropyl  methylcellulose  (HPMC) 
K4M  and  Xanthan  gum  as  release-retarding  agents  for 
diltiazem  HCl  in  the  controlled  release  layer.  Sodium 
bicarbonate was used as the gas generating agent. Dicalcium 
phosphate  was  used  as  the  channeling  agent.  There  was 
significant difference in drug release and floating lag time (P 
< 0.05). HPMC K4M and Xanthan gum retarded the release 
of diltiazem HCl for 12 h. The release of one drug remained 
unaffected in presence of the other drug. In conclusion, such 
kind of combined dosage forms can effectively be formulated 
to deliver more than one drug so as to have improved patient 
compliance and better disease management.
27 
Ling Zhao et al., 2010, hollow microspheres prepared from 
polymer  blends  of  polyvinyl  pyrrolidone  (PVP)  and  ethyl 
cellulose (EC) could improve the vitro release behavior of the 
poorly  water-soluble  drug nifedipine.  Hollow  microspheres 
containing nifedipine were prepared by a solvent diffusion-
evaporation method using various ratios of PVP and EC co-
dissolved with drug in ethanol/ether (5:1, v/v). The hollow 
microspheres could float in release medium for more than 24 
h,  prepared using polymer blends of PVP and EC (1.5:8.5, 
w/w)  could  be  suitable  for  floating-type  controlled-release 
delivery systems for the oral administration of nifedipine.
 28 
Yogesh  S.  et  al.,  2008,  has  studied  formulation  and 
evaluation  of  floating  multiparticulate  oral  drug  delivery 
system  of  diltiazem  hydrochloride,  which  can  provide 
sustained release. The aim was to study various parameters 
affecting  the  behavior  of  floating  multiparticulate  in  oral 
dosage form. Floating microspheres were prepared by non-
aqueous emulsification solvent evaporation technique, using 
ethyl cellulose and Eudragit RS-100 as the rate controlling 
polymer. Results show that the mixing ratio of components in 
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µ  m),  drug  content  (59-84%),  %yield  (57-77%)  and  drug 
release of microsphere (45-99% after 12 h) and floating time 
>12 h. The best results were obtained at the ratio of drug: 
polymer Eudragit RS-100 (1:3).
29 
Baskar  G.Y1.  et  al,  2010,  has  developed  a  floating 
multiparticulate unit system for metoprolol tartarate, using a 
porous carrier, with an outcome for delayed gastric emptying.
 
Methods: Dried microparticles of metoprolol tartarate were 
prepared  by  solvent  evaporation  using  Eudragit®  RS-PO, 
polypropylene foam powder, and dichloromethane as release-
rate modifying polymer, floating aid and solvent respectively. 
The surface topography of the particles was assessed by SEM 
while  the  physical  state  of  the  drug  within  the  developed 
system was characterised by DSC and XRD. Tc99m sulfur 
colloid  radio-labelled  microparticle  formulation  was 
administered to fasting rabbits and their transit behavior was 
monitored  using  gamma  scintigraphy.  The  anterior  and 
posterior images recorded were computed to determine the 
geometric mean counts, enabling quantitative estimation of 
gastric emptying rate.
30 
Chen  R.N.,  et  al,  2010,  has  developed  an  optimal  gastro 
retentive  drug delivery  system  (GRDDS)  for  administering 
Losartan. Additionally, the influence of  optimized GRDDS 
on the bioavailability of Losartan and the formation extent of 
active  metabolite  E3174  by  CYP2C9  polymorphism  was 
investigated.  Swellable  and  floatable  GRDDS  tablets 
combining  hydroxyethyl  cellulose  (HEC),  sodium 
carboxymethyl cellulose (NaCMC), and sodium bicarbonate 
were  prepared  at  various  compression  pressures  for 
evaluating  swelling  characteristics  and  floating  capacity. 
Then Losartan was incorporated into optimized formulations 
for in vitro and in vivo characterizations.
31 
 
Floating Tablet 
Sreekanth  et  al,  2011,  designed  and  evaluate  nifedipine 
floating  matrix  tablets.  Hydroxyprophyl  methyl  cellulose 
(HPMC K100M) was used as a polymer. About 15-35 % of 
HPMC  can  be  used  as  a  polymer  in  the  extended  release 
formulations. So, here the polymer was used in the range of 
16-36  %.  Sodium  bicarbonate  (40%)  is  used  as  a  gas 
generating agent. It can be used in the range of 25-50 %. The 
granules are prepared by wet granulation method. The drug 
release  follows  Korsmeyers  –  Peppas  reaction.  The 
mechanism of drug release is by non-fickian motion. The in 
vitro drug release data indicate that the release of the drug 
depends  upon  the  proportion  of  polymer  present  in  the 
formulation. As the polymer ratio increases the release rate of 
the drug is prolonged.
32 
Gangadharappa  H.V.  et  al,  2010,  formulated  controlled 
release  floating  tablets  of  Atenolol  using  karaya  gum  and 
HPMC as matrix polymers. Atenolol floating tablets based on 
gas formation technique was developed in order to prolong 
the  gastric  residence  time  and  to  increase  the  overall 
bioavailability of the dosage form. It was assumed that this 
form should reside in the stomach floating for several hours 
and gradually release the drug in a controlled way. Sodium 
bicarbonate was incorporated as a gas-generating agent. The 
floating  tablets  were  prepared  by  direct  compression 
technique.  The  effervescent  gastric  floating  drug  delivery 
system  was  a  promising  approach  to  achieve  in  vitro 
buoyancy and to improve the absorption of Atenolol.
33 
Patel  N  Ara  et.  al,  2011,  developed  an  optimized  floating 
drug delivery system of diltiazem hydrochloride. Diltiazem 
floating tablets were formulated with different concentrations 
of two grades of HPMC polymers (HPMC K4M and HPMC 
K100M) by using wet granulation technique. The maximum 
percentage of drug release (99.87 %) and prolonged release 
for  time  period  of  about  12  h,  thereby  improves  the 
bioavailability and patient compliance.
34 
Wu et al, 1997, developed floating sustained release tablets of 
nimodipine  by  using  HPMC  and  PEG  6000.  Prior  to 
formulation of floating tablets, nimodipine was incorporated 
into  poloxamer-188  solid  dispersion  after  which  it  was 
directly compressed into floating tablets. It was observed that 
by  increasing  the  HPMC  and  decreasing  the  PEG  6000 
content a decline in in vitro release of nimodipine occurred.
35 
Moursy  et  al,  2003,  developed  sustained  release  floating 
capsules of nicardipine HCl. For floating, hydrocolloids of 
high  viscosity  grades  were  used  and  to  aid  in  buoyancy 
sodium bicarbonate was added to allow evolution of CO2. In 
vitro analysis of a commercially available 20-mg capsule of 
nicardipine HCl (MICARD) was performed for comparison. 
Results  showed  an  increase  in  floating  with  increase  in 
proportion of hydrocolloid. Inclusion of sodium bicarbonate 
increased buoyancy. The optimized sustained release floating 
capsule  formulation  was  evaluated  in  vivo  and  compared 
with MICARD capsules using rabbits at a dose equivalent to 
a  human  dose  of  40  mg.  Drug  duration  after  the 
administration  of  sustained  release  capsules  significantly 
exceeded that of the MICARD capsules. In the latter case the 
drug was traced for 8 hours compared with16 hours in former 
case.
36 
Zia et al.; 1999, optimized Sotalol floating and bioadhesive 
extended  release  tablet  formulation  which  posses  a  unique 
combination  of  flotation  and  bioadhesion  for  prolong 
residence in the stomach. A new factor factorial design was 
employed to optimize the tablet formulation containing 240 
mg Sotalol HCl, the ratio of NaCMC to HPMC and the ratio 
of  EC  to  Crosspovidone.  The  dependent  variable  was 
dissolution, bioadhesive capability, tablet disintegration and 
required  compression  fource  for  producing  6  kg  hardness 
tablets.
37 
Singh S et al.; 2011, The present study  was undertaken to 
prolong  the  release  of  orally  administer.  Captopril  in  the 
floating  tablets  by  using  different  grade  of 
hydroxypropylrmethylecellulose.  Formulations  were 
optimized  using  different  viscosity  grades  of 
hydroxypropylmethylcellulose.  Three  different  viscosity 
grades  of  hydroxypropylrmethylecellulose  namely  K100M, 
K15M and K4M were used as a floating polymer or intention 
of polymer. It was observed that different viscosities not only 
influence the drug release from hydrophilic matrix but they 
also affect the floating properties of tablets. Results revealed 
that  the  floating  formulation  of  the  Captopril  is  the  best 
formulation  to  obtain  better  therapeutic  effect  and 
hydroxypropylrmethylecellulose  at  a  concentration  of  35% 
up to some extent it increases the Bioavailability of the drug 
to  retain the  dosage  form  on  the  desired  site  for  effective 
period of the time.
38 
Floating Beads 
Iannuccelli,  et  al.,  1998,  formulated  a  air  compartment 
multiple  unit  system  and  optimized  their  in  vitro  floating 
ability. They showed that the floating ability increased with 
increased in PVA concentration and molecular weight and it 
was  found  to  be  excellent  when  using  PVA  100000  at  a 
concentration of at least 5%. 
Takka S. et al.; 1998, The release rate of nicardipine HCl 
from various alginate gel bead formulations was investigated. 
The  formulations  were  prepared  by  utilizing  23  factorial 
design. The effect of drug:polymer weight ratio, CaCl2 and 
sodium-alginate  concentration  on  the  time  for  50%  of  the Yadav Sudhir et al. IRJP 2012, 3 (3) 
Page 101 
drug  to  be  released  (t50%)  and  the  drug  entrapment 
efficiency  were  evaluated  with  analysis  of  variance.  The 
mean particle size and the swelling ratio of the beads were 
determined. The in vitro release studies were carried out by 
flow-through cell apparatus in different media (pH 1.2, 2.5, 
4.5, 7 and 7.5 buffer solutions). Drug: polymer weight ratio 
and the interaction of drug: polymer weight ratio and CaCl2 
concentration had a significant effect on the drug entrapment 
efficiency. The release of nicardipine was extended with the 
alginate  gel  beads,  which  were  prepared  in  a  ratio  of  1:1 
(drug: polymer). The release of drug from alginate gel beads 
took place both by diffusion through the swollen matrix and 
relaxation of the polymer at pH 1.2-4.5. However, the release 
was  due  to  the  diffusion  and  erosion mechanism  at  pH  7-
7.5.
39 
CONCLUSION 
One  of  the  most  feasible  approaches  for  achieving  a 
prolonged  and  predictable  drug  delivery  profiles  in  the 
gastrointestinal tract is to control the gastric residence time 
using gastro retentive dosage forms that will provide us with 
new  and  important  therapeutic  options.  Floating  drug 
delivery  system  can  provide  sufficient  gastric  retention  of 
cardiovascular  drugs  which  may  help  to  provide  sustained 
release  dosage  form  with  enhanced  absorption.  Number  of 
commercial product and patent issued in this field are evident 
of it. 
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